Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary
intervention (PCI) with stent implantation and during one year after PCI, to prevent
atherothrombotic complications. However, clopidogrel is ineffective in certain patients due
to genetic mutation in CYP2C19 gene a specific enzyme in the liver required for metabolism of
clopidogrel. Therefore, the purpose of this study is to test these patients genetically at
bedside and prescribe an alternative drug such as Ticagrelor (90 mg twice daily) or prasugrel
( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight <
60kg) if they are carriers of the allele 2 or 3 of the mutated gene.
Phase:
Phase 4
Details
Lead Sponsor:
Dammam University
Collaborators:
Dammam Central Hospital King Fahad Armed Forces Hospital